Oxytocic drugs are administered intravenously and intramuscularly to stimulate uterine contractions during labor induction for normal child birth and control bleeding after childbirth. Administration of Oxytocic drugs help in both prevention and treatment of postpartum hemorrhage. Oxytocin also is used to reduce bleeding after childbirth. It also may be used along with other medications or procedures to end a pregnancy. Oxytocin is in a class of medications called oxytocic hormones. It works by stimulating uterine contractions. Oxytocin comes as a solution (liquid) to be given intravenously (into a vein) or intramuscularly (into the muscle) by a doctor or healthcare provider in a hospital or clinic. If oxytocin injection is given to induce labor or to increase contractions, it is usually given intravenously with medical supervision in a hospital. According to the American College of Obstetricians and Gynecologists (ACOG) prophylactic administration of uterotonic agents to prevent uterine atony is recommended. Furthermore, increasing childbirth using labor induction is expected to boost growth of the global oxytocic pharmaceuticals market over the forecast period.
Market Dynamics
The key market players are focusing on adoption of growth strategies such as partnership and acquisitions, to bring in the development of uterine contractility drugs which is attributed to the growth of global oxytocic pharmaceutical market. For instance, in February 2022, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in adults and newborns. In adults, Prader-Willi causes hyperphagia, or pathological over-eating, which leads to obesity and other complications associated with significant mortality. In newborns, Prader-Willi causes a deficiency in suckling, which has been shown to be normalized by oxytocin treatment.
Key features of the study:
Detailed Segmentation:
Table of Contents
*Browse 34 market data tables and 26 figures on “Oxytocic Pharmaceuticals Market” – Global forecast to 2030
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients